The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).
Denise A. Yardley
No relevant relationships to disclose
Paul D. Richards
No relevant relationships to disclose
James Andrew Reeves
No relevant relationships to disclose
Elizabeth Claire Dees
Research Funding - Genentech; GlaxoSmithKline; Lilly; Millennium; Novartis
Cynthia R. C. Osborne
No relevant relationships to disclose
Hatem Hussein Soliman
No relevant relationships to disclose
Devchand Paul
No relevant relationships to disclose
Foluso Olabisi Ademuyiwa
No relevant relationships to disclose
Troy H. Guthrie
No relevant relationships to disclose
Jane L. Bromund
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Yihuan Xu
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Ayman B. Ibrahim
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly